Oura's May 2026 confidential S-1 filing and rapid revenue expansion—on pace for roughly $1 billion in 2025 sales and approaching $2 billion in 2026—anchor trader sentiment around a potential uplift from its $11 billion October 2025 Series E valuation. Strong paid-member growth and a recurring-revenue model support higher multiples, yet the closely bunched probabilities across $10–20 billion ranges and the 13.9% chance of no IPO before January 2027 reflect uncertainty over IPO-window timing, comparable 2026 tech listings, and execution in a still-selective market. Key swing factors include final SEC clearance, underwriter positioning, and any macro shifts affecting risk appetite for health-tech names.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$20B+ 16%
$10B–$12.5B 14%
No IPO before January 2027 13.7%
$15B–$17.5B 12%
$170,553 Wol.
$170,553 Wol.
Jan 1, 2027
<$7.5B
9%
$7.5B–$10B
11%
$10B–$12.5B
14%
$12.5B–$15B
11%
$15B–$17.5B
12%
$17.5B–$20B
12%
$20B+
16%
No IPO before January 2027
14%
$20B+ 16%
$10B–$12.5B 14%
No IPO before January 2027 13.7%
$15B–$17.5B 12%
$170,553 Wol.
$170,553 Wol.
Jan 1, 2027
<$7.5B
$18,907 Wol.
9%
$7.5B–$10B
$27,466 Wol.
11%
$10B–$12.5B
$22,283 Wol.
14%
$12.5B–$15B
$49,969 Wol.
11%
$15B–$17.5B
$13,741 Wol.
12%
$17.5B–$20B
$16,457 Wol.
12%
$20B+
$16,430 Wol.
16%
No IPO before January 2027
$5,299 Wol.
14%
This market will resolve based on Oura's market capitalization at the closing price on its first day of trading.
If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.Oura's May 2026 confidential S-1 filing and rapid revenue expansion—on pace for roughly $1 billion in 2025 sales and approaching $2 billion in 2026—anchor trader sentiment around a potential uplift from its $11 billion October 2025 Series E valuation. Strong paid-member growth and a recurring-revenue model support higher multiples, yet the closely bunched probabilities across $10–20 billion ranges and the 13.9% chance of no IPO before January 2027 reflect uncertainty over IPO-window timing, comparable 2026 tech listings, and execution in a still-selective market. Key swing factors include final SEC clearance, underwriter positioning, and any macro shifts affecting risk appetite for health-tech names.
This market will resolve based on Oura's market capitalization at the closing price on its first day of trading.
If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.
If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.
Rynek otwarty: May 26, 2026, 12:28 PM ET
Wolumen
$170,553Data zakończenia
Jan 1, 2027Rynek otwarty
May 26, 2026, 12:28 PM ETResolver
0x69c47De9D...This market will resolve based on Oura's market capitalization at the closing price on its first day of trading.
If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.Oura's May 2026 confidential S-1 filing and rapid revenue expansion—on pace for roughly $1 billion in 2025 sales and approaching $2 billion in 2026—anchor trader sentiment around a potential uplift from its $11 billion October 2025 Series E valuation. Strong paid-member growth and a recurring-revenue model support higher multiples, yet the closely bunched probabilities across $10–20 billion ranges and the 13.9% chance of no IPO before January 2027 reflect uncertainty over IPO-window timing, comparable 2026 tech listings, and execution in a still-selective market. Key swing factors include final SEC clearance, underwriter positioning, and any macro shifts affecting risk appetite for health-tech names.
This market will resolve based on Oura's market capitalization at the closing price on its first day of trading.
If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.
If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.
Wolumen
$170,553Data zakończenia
Jan 1, 2027Rynek otwarty
May 26, 2026, 12:28 PM ETResolver
0x69c47De9D...Oura's May 2026 confidential S-1 filing and rapid revenue expansion—on pace for roughly $1 billion in 2025 sales and approaching $2 billion in 2026—anchor trader sentiment around a potential uplift from its $11 billion October 2025 Series E valuation. Strong paid-member growth and a recurring-revenue model support higher multiples, yet the closely bunched probabilities across $10–20 billion ranges and the 13.9% chance of no IPO before January 2027 reflect uncertainty over IPO-window timing, comparable 2026 tech listings, and execution in a still-selective market. Key swing factors include final SEC clearance, underwriter positioning, and any macro shifts affecting risk appetite for health-tech names.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania